Laboratory monitoring during isotretinoin therapy for acne a systematic review and meta-analysis

JAMA Dermatology

Volumn 152, Issue 1, 2016, Pages 35-44

  Lee, Young H ^a   Scharnitz, Thomas P ^b   Muscat, Joshua ^c   Chen, Allshine ^c   Gupta Elera, Gaytri ^b   Kirby, Joslyn S ^c  

^a Sharp Rees Stealy Medical Group   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOTRETINOIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; DERMATOLOGICAL AGENT;

ACNE VULGARIS; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; GOOD LABORATORY PRACTICE; HIGH RISK PATIENT; HUMAN; LABORATORY MONITORING; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MEDICAL LITERATURE; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; META ANALYSIS; ORAL DRUG ADMINISTRATION; PROCEDURES;

ACNE VULGARIS; ADMINISTRATION, ORAL; DERMATOLOGIC AGENTS; DRUG MONITORING; HUMANS; ISOTRETINOIN;

EID: 84955255446     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.3091     Document Type: Article

References (63)

1. Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. An Bras Dermatol. 2012;87(3): 382-387.
2. Flynn WJ, Freeman PG, Wickboldt LG. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann Intern Med. 1987;107(1): 63.
3. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016-1022.
4. Roche Laboratories. Accutane (isotretinoin capsules). http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/018662s059lbl.pdf. Published November 2008. Accessed July 5, 2014.
5. Alcalay J, Landau M, Zucker A. Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests? J Dermatolog Treat. 2001; 12(1):9-12.
6. Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol. 1993;129(6):704-707.
7. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology. 2002;204(3):232-235.
8. Hansen T, Zaenglein A, Miller J. Standardizing laboratory monitoring of patients undergoing isotretinoin treatment using a cost-effective and best evidence approach [abstract]. J Am Acad Dermatol. 2013;68(4)(suppl 1):AB6.
9. University of York Centres for Reviews and Dissemination. PROSPERO database: laboratory monitoring during treatment with isotretinoin. Registration CRD42014010494. http://www.crd.york.ac.uk/prospero. Accessed July 3, 2014.
10. National Institutes of Health. Clinical Center Test Guide: Lipid Panel. Washington, DC: US Dept of Health and Human Services; 2015.
11. National Institutes of Health. Clinical Center Test Guide: Hepatic Panel. Washington, DC: US Dept of Health and Human Services; 2015.
12. Ragos G, Houlden R, Danby FW. Effect of isotretinoin therapy on serum total cholesterol and triglycerides. Can J Clin Pharmacol. 1998;5(1):43-47.
13. Buckley D, Rogers S, Daly P. Isotretinoin therapy for acne vulgaris: results in an Irish population. Ir J Med Sci. 1990;159(1):2-5.
14. Erturan I, Naziroglu M, Akkaya VB. Isotretinoin treatment induces oxidative toxicity in blood of patients with acne vulgaris: a clinical pilot study. Cell Biochem Funct. 2012;30(7):552-557.
15. Michaëlsson G, Vahlquist A, Mobacken H, et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol. 1986;66(2):144-148.
16. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985; 313(16):981-985.
17. Hanstad IK, Thune P. Nodulocystic acne: treatment with isotretinoin (Roaccutan)-quantitative measures of skin lipids [in Norwegian]. Tidsskr Nor Laegeforen. 1985;105(23):1497-1500.
18. Pigatto PD, Finzi AF, Altomare GF, Polenghi MM, Vergani C, Vigotti G. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica. 1986;172(3):154-159.
19. Laker MF, Green C, Bhuiyan AK, Shuster S. Isotretinoin and serum lipids: studies on fatty acid, apolipoprotein and intermediary metabolism. Br J Dermatol. 1987;117(2):203-206.
20. Melnik B, Bros U, Plewig G. Characterization of apoprotein metabolism and atherogenic lipoproteins during oral isotretinoin treatment. Dermatologica. 1987;175(suppl 1):158-168.
21. Lyons F, Laker MF, Marsden JR, Manuel R, Shuster S. Effect of oral 13-cis-retinoic acid on serum lipids. Br J Dermatol. 1982;107(5):591-595.
22. Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol. 1983;108(3):333-343.
23. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490-496.
24. Ostlere LS, Harris D, Morse-Fisher N, Wright S. Effect of systemic administration of isotretinoin on blood lipids and fatty acids in acne patients. Int J Dermatol. 1996;35(3):216-218.
25. Strauss JS, Leyden JJ, Lucky AW, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol. 2001;45(2):196-207.
26. Ferahbas A, Turan MT, Esel E, Utas S, Kutlugun C, Kilic CG. A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J Dermatolog Treat. 2004;15(3):153-157.
27. Koistinen HA, Remitz A, Koivisto VA, Ebeling P. Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic. Diabetologia. 2006;49(2):383-386.
28. Polat M, Lenk N, Bingöl S, et al. Plasma homocysteine level is elevated in patients on isotretinoin therapy for cystic acne: a prospective controlled study. J Dermatolog Treat. 2008;19(4): 229-232.
29. Roodsari MR, Akbari MR, Sarrafi-rad N, Saeedi M, Gheisari M, Kavand S. The effect of isotretinoin treatment on plasma homocysteine levels in acne vulgaris. Clin Exp Dermatol. 2010;35(6):624-626.
30. Ertugrul DT, Karadag AS, Tutal E, Akin KO. Isotretinoin does not induce insulin resistance in patients with acne. Clin Exp Dermatol. 2011;36(2): 124-128.
31. Dursun R, Alpaslan M, Caliskan M, et al. Isotretinoin does not prolong QT intervals and QT dispersion in patients with severe acne: a surprising finding for a drug with numerous side effects. J Drugs Dermatol. 2011;10(7):710-714.
32. Karadag AS, Tutal E, Ertugrul DT, Akin KO. Effect of isotretinoin treatment on plasma holotranscobalamin, vitamin B12, folic acid, and homocysteine levels: non-controlled study. Int J Dermatol. 2011;50(12):1564-1569.
33. Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev. 2001;17(5):391-395.
34. Rødland O, Aksnes L, Nilsen A, Morken T. Serum levels of vitamin D metabolites in isotretinoin-treated acne patients. Acta Derm Venereol. 1992;72(3):217-219.
35. Hoting VE, Schütte B, Schirren C. Isotretinoin treatment of acne conglobate: andrologic follow-up [in German]. Fortschr Med. 1992;110(23):427-430.
36. Bruhat MA, Mage G, Manhes H, Pouly JL, Jacquetin B. The indication for laparoscopy in female infertility [in French]. J Gynecol Obstet Biol Reprod (Paris). 1980;9(3):337-340.
37. Meigel W, Gollnick H, Wokalek H, Plewig G. Oral treatment of acne conglobata using 13-cis-retinoic acid: results of the German multicentric study following 24 weeks of treatment [in German]. Hautarzt. 1983;34(8):387-397.
38. Plewig G, Gollnick H, Meigel W, Wokalek H. 13-Cis retinoic acid in the oral therapy of acne conglobate: results of a multi-center study [in German]. Hautarzt. 1981;32(12):634-646.
39. Wagner A, Plewig G. 13-Cis-retinoic acid: pharmacologic and toxicologic findings in treatment of severe forms of acne [in German]. MMW Munch Med Wochenschr. 1980;122(38):1294-1300.
40. Effects of isotretinoin on plasma lipids and lipoproteins. Nutr Rev. 1986;44(6):196-198.
41. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin: a prospective study. Arch Dermatol. 1983;119(12): 987-993.
42. Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J Dermatolog Treat. 2006;17(4):214-216.
43. Wahab R, Rahman M, Monamie N, Jamaluddin M, Khondker L, Afroz W. Isotretinoin vs weekly pulse dose azithromycin in the treatment of acne-a comparative study. J Pak Assoc Dermatol. 2008;18: 9-14.
44. Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial. Indian J Dermatol Venereol Leprol. 2011;77(6):688-694.
45. Ahmed I, Wahid Z, Nasreen S. Adverse effects of systemic isotretinoin therapy: a study of 78 patients. J Pak Assoc Dermatol. 2005;15:242-246.
46. Tallab T, Joharji H, Jazei M, Bahamdan K, Ibrahim K, Karkashan E. Isotretinoin therapy: any need for laboratory assessment? West Afr J Med. 2004;23(4):273-275.
47. Sadick NA. Practitioner's 10-year experience with isotretinoin and side effect profiles. Int J Cosmet Surg Aesthetic Dermatol. 2002;4(2):89-94.
48. Ng PP, Goh CL. Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients. Int J Dermatol. 1999;38(3):213-216.
49. Spear KL, Muller SA. Treatment of cystic acne with 13-cis-retinoic acid. Mayo Clin Proc. 1983;58 (8):509-514.
50. Hermes B, Praetel C, Henz BM. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol. 1998;11(2):117-121.
51. van der Meeren HL, van der Schroeff JG, Stijnen T, van Duren JA, van der Dries HA, van Voorst Vader PC. Dose-response relationship in isotretinoin therapy for conglobate acne. Dermatologica. 1983; 167(6):299-303.
52. Shahidullah M, Tham SN, Goh CL. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol. 1994;33(1):60-63.
53. Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576-580.
54. Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol. 2012;51(9):1123-1130.
55. Gandola M. Therapy of severe acne and acne rosacea with oral 13-cis-retinoic acid (isotretinoin) [in Italian]. Acta Vitaminol Enzymol. 1984;6(4):325-337.
56. Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33(5):484-486, 489.
57. Entezari-Maleki T, Hadjibabaeil M, Salamzadeh J, Javadil MR, Shalviri G, Gholamil K. Evaluation and monitoring of isotretinoin use in Iran. Arch Iran Med. 2012;15(7):409-412.
58. Gollnick H, Luley C, Schwartzkopff W, Orfanos CE. Changes in serum lipid fractions as a side effect of oral retinoids [in German]. Z Hautkr. 1982;57(17): 1255-1267.
59. O'Leary TJ, Simo IE, Kanigsberg N, Walker J, Goodall JC, Ooi TC. Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy. Clin Invest Med. 1987;10(4): 355-360.
60. Amblard P, Beani JC, Reymond JL, Didier B, Coignet M. Our experience of isotretinoin in the treatment of severe acne for about 421 treated patients [in French]. Sem Hop Ther Paris. 1986; 62(1-2):61-66.
61. Almond-Roesler B, Blume-Peytavi U, Bisson S, Krahn M, Rohloff E, Orfanos CE. Monitoring of isotretinoin therapy by measuring the plasma levels of isotretinoin and 4-oxo-isotretinoin: a useful tool for management of severe acne. Dermatology. 1998;196(1):176-181.
62. McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol. 1991;127(3):341-346.
63. Al-Mutairi N, Manchanda Y, Nour-Eldin O, Sultan A. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol. 2005;4(3):369-373.